Hydroxy-Methylglutaryl-Coenzyme a reductase inhibition improves endothelial dysfunction in type-1 diabetes

European Journal of Vascular and Endovascular Surgery

Volumn 27, Issue 4, 2004, Pages 432-437

  Joyce, Myles ^a,b   Moore, K ^a   Thompson, C ^a   Fitzgerald, P ^a   Fennessy, F ^a   Kelly, C J ^a   Bouchier Hayes, D J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b MAYO GENERAL HOSPITAL   (Ireland)

Author keywords

Constitutive endothelial nitric oxide synthase; Diabetes mellitus; Endothelial dysfunction; HMG CoA reductase inhibition; Nitric oxide

Indexed keywords

BIOCHEMICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PRAVASTATIN;

ADULT; AGE; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; ECHOGRAPHY; ENDOTHELIUM LESION; ENZYME INHIBITION; GENDER; HUMAN; HYPEREMIA; HYPOTHESIS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 1642357320     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2003.12.020     Document Type: Article

References (46)

1. Colwell JA, Lopes-Vivella MF. A review of the development of large vessel disease in diabetes mellitus. Am J Med 1998;28:113-118.
2. Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary disease in juvenile artery disease in juvenile onset insulin dependent diabetes mellitus. Am J Cardiol 1987; 59:750-755.
3. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes. Hypertension 1998; 31:1047-1060.
4. Honing MLH, Morrison PJ, Banga JD et al. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998; 14: 241-249.
5. Clarkson P, Celermajer DS, Donald AE et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28:573-579.
6. Lehmann ED, Riley WA, Clarkson P et al. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 1997; 350:14-19.
7. Loscalzo J. What we know and don't know about L-arginine and NO. Circulation 2000; 101:2126-2129.
8. Byington RP, Jukema JW, Salonen JT et al. Reduction in cardiovascular events during pravastatin therapy Circulation 1995; 92:2419-2425.
9. Scandinavian Simvastatin Survival Study Investigators, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
10. Shepherd J, Cobbe S, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study. N Engl J Med 1995; 333: 1301-1307.
11. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87:1781-1791.
12. Ikeda U, Shimpo M, Ohki R et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000; 36:325-329.
13. Essig M, Nguyen G, Prié D et al. 3-hydroxy-3-Methylglut taryl coenzyme a reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Cir Res 1998; 83:683-690.
14. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348:1079-1082.
15. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28:2315-2320.
16. Sacks FM, Pfeffer MA, Moye LA, for the Cholesterol and Recurrent Events Trial Investigators et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
17. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1-month. Circulation 1997; 95:1126-1131.
18. Stefan J, Schlaich M, Langenfeld M et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 1998; 98:211-216.
19. Laufs U, Fata VL, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA Reductase inhibitors. Circulation 1998; 97:1129-1135.
20. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33:234-241.
21. Thorne S, Mullen MJ, Clarkson P et al. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998; 32:110-116.
22. Ewald U, Kobbah M, Tuvemo T. Vascular reactivity and platelet aggregability during the first five years of insulin-dependent diabetes in children. Acta Paediatr 1997; 418:15-20.
23. Lambert J, Aarsen M, Donyer AJM, Stenhouwer CDA. Endothelium-dependent and independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16:705-711.
24. O'Driscoll G, Green D, Rankin J et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100(3):678-684.
25. Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755.
26. Agewall S, Wright S, Doughty RN et al. Does a glass of red wine improve endothelial function? Eur Heart J 2000; 21:74-78.
27. Meeking DR, Cummings MH, Thorne S et al. Endothelial dysfunction in type 1 diabetic subjects with and without microalbuminuria. Diabetic Med 1999; 16:841-847.
28. Clarkson P, Mullen MJ, Donald AE et al. The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. Atherosclerosis 2001; 154:171-177.
29. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
30. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323:27-36.
31. Stehouwer CDA, Lambert J, Donker AJM, Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34:55-68.
32. McNally PG, Watt PAC, Rimmer T et al. Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin dependent diabetes mellitus. Clin Sci 1994; 87:31-36.
33. Johnstone MT, Creager SJ, Scales KM et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes. Circulation 1993; 88:2510-2516.
34. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol 1999; 34:146-154.
35. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.
36. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-Methylglutaryl-Coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103:113-118.
37. Wascher TC, Graier WF, Bahadori B, Toplak H. Time course of endothelial dysfunction in diabetes mellitus. Circulation 1994; 90:1109.
38. Sorensen KE, Celermajer DS, Spiegelhalter DJ et al. Non-invasive mesurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-253.
39. Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycaemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97:1695-1701.
40. Lehmann ED, Riley WA, Clarkson P, Gosling RG. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 1997; 350(Suppl. I):14-19.
41. Piper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29:8-15.
42. O'Driscoll G, Green D, Rankin J et al. Improvement in endothelial function by angiotensin converting enzyme in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100(3): 678-684.
43. Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes 1995; 44:721-726.
44. Joyce M, Kelly CJ, Chen G, Bouchier-Hayes DJ. Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase. Eur J Vasc Endovasc Surg 2001; 21(4):295-300.
45. Anderson TJ, Uehata A, Gerhard MD et al. Close relation of endothelial function in the human coronary artery and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-1241.
46. Endres M, Laufs U, Huang Z, Nakamura T et al. Stroke protection by 3-hydroxy 3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95:8880-8885.